MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Annals of the Rheumatic Diseases
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,612 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,612 works in the cohort · of 4,299,418page 15 of 53

Labels cover 7 of 2,612 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,612 of 2,612 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

afffundno abstractunlabeled
OP0228 EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS, INCLUDING PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC THERAPIES: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, KEEPSAKE 2 TRIAL
Andrew J.K. Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion +6 more
2021· article· en· Annals of the Rheumatic Diseases· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
10
citations
affno abstractunlabeled
SAT0151 EFFICACY AND SAFETY OF UPADACITINIB VERSUS ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-CHOICE): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
Andrea Rubbert‐Roth, Jeffrey Enejosa, Aileen L. Pangan, Ricardo Machado Xavier, Boulos Haraoui, Maureen Rischmueller +4 more
2020· article· en· Annals of the Rheumatic Diseases· Medicine
machine prediction:candidate · noneconsensus · none
10
citations
affno abstractunlabeled
Gout risk in adults with pre-diabetes initiating metformin
Javier Marrugo, L Santacroce, Misti L. Paudel, Sho Fukui, Alexander Turchin, Sara K. Tedeschi +1 more
2024· article· en· Annals of the Rheumatic Diseases· Medicine
machine prediction:candidate · noneconsensus · none
9
citations
affno abstractunlabeled
SAT0575 Safety and efficacy of lutikizumab (ABT-981), an anti–interleukin-1 alpha/beta dual variable domain (DVD) immunoglobulin, in subjects with knee osteoarthritis: results from the randomised, double-blind, placebo-controlled, parallel-group phase 2 trial
Roy Fleischmann, Henning Bliddal, Francisco J. Blanco, Thomas J. Schnitzer, C. Peterfy, S. Chen +11 more
2018· article· en· Annals of the Rheumatic Diseases· Medicine
machine prediction:candidate · noneconsensus · none
9
citations
affunlabeled
Plasma proteome profiling in giant cell arteritis
Kevin Y. Cunningham, Benjamin Hur, Vinod K. Gupta, Matthew J. Koster, Cornelia M. Weyand, D. P. Cuthbertson +12 more
2024· article· en· Annals of the Rheumatic Diseases· Medicine
machine prediction:candidate · noneconsensus · none
8
citations

How this was built: Screen · Findings · About